{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T03:49:44Z","timestamp":1775879384490,"version":"3.50.1"},"reference-count":26,"publisher":"Japanese Circulation Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2026,4,10]]},"DOI":"10.1253\/circrep.cr-25-0208","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T22:09:34Z","timestamp":1768946974000},"page":"595-602","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Pre-Existing Cardiovascular and Metabolic Conditions on the Development of Heart Failure After Paclitaxel Therapy\u3000\u2015 Real-World Study Based on a Nationwide Claims Database in Japan \u2015"],"prefix":"10.1253","volume":"8","author":[{"given":"Shiori","family":"Iwane","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Setsunan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Setsunan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyoshi","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hyogo Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Nishida","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Setsunan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Hasebe","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Setsunan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Kikuta","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Setsunan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Setsunan University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: Cardio-oncology. <i>Mayo Clin Proc<\/i> 2014; 89: 1287\u20131306, doi:10.1016\/j.mayocp.2014.05.013.","DOI":"10.1016\/j.mayocp.2014.05.013"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation<\/i> 2022; 145: e895\u2013e1032, doi:10.1161\/cir.0000000000001063.","DOI":"10.1161\/CIR.0000000000001063"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Inoue K, Machino-Ohtsuka T, Nakazawa Y, Iida N, Sasamura R, Bando H, et al. Early detection and prediction of anthracycline-induced cardiotoxicity: Prospective cohort study. <i>Circ J<\/i> 2024; 88: 751\u2013759, doi:10.1253\/circj.CJ-24-0065.","DOI":"10.1253\/circj.CJ-24-0065"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Yamada K, Tamura Y, Taniguchi H, Furukawa A, Iwasawa J, Yada H, et al. Usefulness of global longitudinal strain-guided management in preventing human epidermal growth factor receptor 2 (HER2) inhibitor-induced myocardial damage. <i>Circ Rep<\/i> 2022; 4: 526\u2013532, doi:10.1253\/circrep.CR-22-0094.","DOI":"10.1253\/circrep.CR-22-0094"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Ozaki R, Morimoto R, Kazama S, Hiraiwa H, Kondo T, Takano Y, et al. Cancer therapy-related cardiac dysfunction in patients with human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab and pertuzumab. <i>Circ Rep<\/i> 2025; 7: 800\u2013808, doi:10.1253\/circrep.CR-25-0036.","DOI":"10.1253\/circrep.CR-25-0036"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Ma Y, Grootaert MOJ, Sewduth RN. Cardiotoxicity of chemotherapy: A multi-OMIC perspective. <i>J Xenobiot<\/i> 2025; 15: 9, doi:10.3390\/jox15010009.","DOI":"10.3390\/jox15010009"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Del Mastro L, Perrone F, Repetto L, Manzione L, Zagonel V, Fratino L, et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: A phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). <i>Ann Oncol<\/i> 2005; 16: 253\u2013258, doi:10.1093\/annonc\/mdi056.","DOI":"10.1093\/annonc\/mdi056"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Osman M, Elkady M. A prospective study to evaluate the effect of paclitaxel on cardiac ejection fraction. <i>Breast Care (Basel)<\/i> 2017; 12: 255\u2013259, doi:10.1159\/000471759.","DOI":"10.1159\/000471759"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Morelli MB, Bongiovanni C, Da Pra S, Miano C, Sacchi F, Lauriola M, et al. Cardiotoxicity of anticancer drugs: Molecular mechanisms and strategies for cardioprotection. <i>Front Cardiovasc Med<\/i> 2022; 9: 847012, doi:10.3389\/fcvm.2022.847012.","DOI":"10.3389\/fcvm.2022.847012"},{"key":"10","unstructured":"10. Kamineni P, Prakasa K, Hasan SP, Akula R, Dawkins F. Cardiotoxicities of paclitaxel in African Americans. <i>J Natl Med Assoc<\/i> 2003; 95: 977\u2013981."},{"key":"11","unstructured":"11. John P, Butler H, Saif MW. Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer. <i>Anticancer Res<\/i> 2014; 34: 7267\u20137270."},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T. Data resource profile: JMDC claims databases sourced from medical institutions. <i>J Gen Fam Med<\/i> 2020; 21: 211\u2013218, doi:10.1002\/jgf2.367.","DOI":"10.1002\/jgf2.367"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. <i>Bone Marrow Transplant<\/i> 2013; 48: 452\u2013458, doi:10.1038\/bmt.2012.244.","DOI":"10.1038\/bmt.2012.244"},{"key":"14","unstructured":"14. Arbuck SG, Strauss H, Rowinsky E, Christian M, Suffness M, Adams J, et al. A reassessment of cardiac toxicity associated with Taxol. <i>J Natl Cancer Inst Monogr<\/i> 1993; (15): 117\u2013130."},{"key":"15","unstructured":"15. Sakusabe M, Ouchi S, Seki H, Kumagai Y, Kamata S, Kotanagi H. A case of effective weekly paclitaxel administration for gastric cancer recurrence with carcinomatous pericarditis. <i>Gan To Kagaku Ryoho<\/i> 2005; 32: 77\u201379 (in Japanese)."},{"key":"16","unstructured":"16. Tsujita T, Kuronuma K, Hata N. A case in which good control of carcinomatous serositis was achieved using chemotherapy including albumin-bound paclitaxel (nab-PTX) for advanced-stage pulmonary adenocarcinoma exhibiting carcinomatous pleurisy and carcinomatous pericarditis. <i>Gan To Kagaku Ryoho<\/i> 2018; 45: 1181\u20131184 (in Japanese)."},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Gollerkeri A, Harrold L, Rose M, Jain D, Burtness BA. Use of paclitaxel in patients with pre-existing cardiomyopathy: A review of our experience. <i>Int J Cancer<\/i> 2001; 93: 139\u2013141, doi:10.1002\/ijc.1295.","DOI":"10.1002\/ijc.1295"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Singh H, Ahmed O, Allen E, Othman H. A case of stress cardiomyopathy with nab-paclitaxel infusion. <i>J Investig Med High Impact Case Rep<\/i> 2023; 11: 23247096231209554, doi:10.1177\/23247096231209554.","DOI":"10.1177\/23247096231209554"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Micho Ulbeh T, Sara A, Uddin MM, Bell K, Elmograbi A, Cardozo S. Takotsubo cardiomyopathy caused by infusion reaction to paclitaxel. <i>BMJ Case Rep<\/i> 2021; 14: e243863, doi:10.1136\/bcr-2021-243863.","DOI":"10.1136\/bcr-2021-243863"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. Vascular toxicities of cancer therapies: The old and the new--an evolving avenue. <i>Circulation<\/i> 2016; 133: 1272\u20131289, doi:10.1161\/circulationaha.115.018347.","DOI":"10.1161\/CIRCULATIONAHA.115.018347"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. <i>Cancer Treat Rev<\/i> 2004; 30: 181\u2013191, doi:10.1016\/j.ctrv.2003.07.003.","DOI":"10.1016\/j.ctrv.2003.07.003"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. <i>J Clin Oncol<\/i> 1996; 14: 2713\u20132721, doi:10.1200\/jco.1996.14.10.2713.","DOI":"10.1200\/JCO.1996.14.10.2713"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Gianni L, Vigan\u00f2 L, Locatelli A, Capri G, Giani A, Tarenzi E, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. <i>J Clin Oncol<\/i> 1997; 15: 1906\u20131915, doi:10.1200\/jco.1997.15.5.1906.","DOI":"10.1200\/JCO.1997.15.5.1906"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Gianni L, Dombernowsky P, Sledge G, Martin M, Amadori D, Arbuck SG, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer. <i>Ann Oncol<\/i> 2001; 12: 1067\u20131073, doi:10.1023\/a:1011655503511.","DOI":"10.1023\/A:1011655503511"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Jerian S, Keegan P. Cardiotoxicity associated with paclitaxel\/trastuzumab combination therapy. <i>J Clin Oncol<\/i> 1999; 17: 1647\u20131648.","DOI":"10.1200\/JCO.1999.17.5.1644e"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Johnson D, Weisleder H, Yuan H, Carrozzi G. Paclitaxel-induced myocarditis presenting as new-onset heart failure. <i>BMJ Case Rep<\/i> 2024; 17: e255646, doi:10.1136\/bcr-2023-255646.","DOI":"10.1136\/bcr-2023-255646"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/4\/8_CR-25-0208\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T03:22:25Z","timestamp":1775877745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/4\/8_CR-25-0208\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-25-0208","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"CR-25-0208"}}